Summary: <br> <a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.talkingbiotechpodcast.com%2F313-rediscovery-of-new-cancer-drugs%2F&via=talkingbiotech" class="twitter-share-button" data-size="large">Tweet</a><br> <a href="https://i0.wp.com/www.talkingbiotechpodcast.com/wp-content/uploads/2021/10/313-Bakker-cover.jpg"></a><br> Drug pipelines are thick with novel compounds that may have an effect on our most insidious diseases. However, most either fail early trials or are withdrawn because companies don’t see the return on investment of driving them forward. These shelved compounds still may have important roles in treating orphan diseases. The Children’s Tumor Foundation identifies these compounds lost to corporate expectations and re-analyzes them for therapeutic potential for other indications. Dr. Annette Bakker describes the process, the potential and the promise of compounds already identified in this partnership with pharmaceutical companies– testing their throwaways for new applications.<br>
